Business
NRx Pharmaceuticals to Report Year-End 2021 Results on March 31, 2022
--Company to Host Conference Call March 31, 2022, at 8:30AM ET--- RADNOR, Pa., March 28, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) ("NRx
About this update from Nrx Pharmaceuticals, Inc.
[{"type":"text","content":"--Company to Host Conference Call March 31, 2022, at 8:30AM ET---\nRADNOR, Pa., March 28, 2022 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\"), a clinical-stage, biopharmaceutical company today announced that management will report year end 2021 financial results prior to the market open on March 31, 2022. The company will host a conference call and webcast on March 31, 2022, 8:30AM Eastern Time to discuss its results and provide a clinical and corporate update. Management will host the call, followed by a question-and-answer period. Investors interested in submitting questions must do so in advance of the call and are encouraged to email questions to the Company's investor relations representative at [email protected] by 4:00 PM Eastern Time on March 29, 2022.\n\n \n \n \n \n \n \n\n \nInvestors and the general public are invited to listen to a live audio webcast of the conference call, which may be accessed five minutes prior to the start of the call by dialing (877) 407-9716 (U.S.), (201) 493-6779 (International) Conference ID: 13728080, or through the webcast link NRx Pharmaceuticals Year End Results Call. A replay will be available from the NRx Pharmaceuticals website following the call at www.nrxpharma.com.\nAbout NRx Pharmaceuticals\nNRx Pharmaceuticals, Inc. (Nasdaq: NRXP) (\"NRx Pharmaceuticals\" or the \"Company\") draws upon decades of collective, scientific, and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI® (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration (FDA) and is in several Phase II/III studies including a Phase III trial for Critical COVID-19 patients which is sponsored and managed by the US National Institutes of Health, and a Phase II study funded by the Biomedical Advanced Research and Development Authority (BARDA) of the US Department of Health and Human Services. The FDA has additionally granted Breakthrough Therapy designation, a Special Protocol Agreement, and a Biomarker Letter of Support for NRX-101, an investigational medicine for the treatment of severe bipolar depression in patients with acute suicidal ideation and behavior (ASIB) after initial stabilization with ketamine or other effective therapy.\nNRx Pharmaceuticals is led...